Pentoxifylline Neuroprotective Effects Are Possibly Related to Its Anti-Inflammatory and TNF-Alpha Inhibitory Properties, in the 6-OHDA Model of Parkinson’s Disease

Figure 6

Representative photomicrographs showing that pentoxifylline treatments (PTX, 15 days) reverse the increased immunoreactivity for tyrosine hydroxylase (TH) in the 6-OHDA group, relatively to the substantia nigra and striatum of the untreated 6-OHDA group. Groups: SO (sham-operated, control), untreated 6-OHDA, and 6-OHDA treated with PTX, at the doses of 25 and 50 mg/kg. Ipsilateral = lesioned side. Magnifications: 40 and 400x. Substantia nigra: A versus SO, q = 11.76 ; B versus 6-OHDA + PTX25, q = 7.200 ; C versus 6-OHDA + PTX50, q = 11.35 ; D versus SO, = 4.556 ; E versus 6-OHDA + PTX25, q = 4.149 . Striatum: A versus SO, q = 12.26 ; B versus 6-OHDA + PTX25, q = 7.850 ; C versus 6-OHDA + PTX50, q = 11.31 ; D versus SO, q = 4.408 , E versus 6-OHDA + PTX25, q = 3.458 (one-way ANOVA and Newman-Keuls as the post hoc test).

(a) Substantia nigra

(b) Striatum